EGFR exon 20 insertion

Indianapolis, Indiana, September 15, 2026 Eli Lilly and Company will present new clinical and scientific data for Foundayo (orforglipron),...

Princeton, New Jersey, September 15, 2026 Taiho Oncology has announced positive results from the REZILIENT3 Phase 3 trial, showing...

Raritan, New Jersey, U.S., September 14, 2026 Johnson & Johnson announced new overall survival data from the Phase III...

San Mateo, California, August 12, 2026 Mendaera Inc. announced results from a new peer-reviewed prospective multispecialty study showing that...

Brisbane, California, August 12, 2026 Freenome, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...

Princeton, New Jersey, Tokyo, Japan & Cambridge, Massachusetts, August 12, 2026 Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced...

SHANGHAI, China, July 14, 2026 Dizal has entered into a landmark global exclusive license agreement with AstraZeneca for Zegfrovy...

CAMBRIDGE, Mass., May 27, 2026 Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on developing precisely targeted cancer therapies, has...

SHANGHAI, China, May 27, 2026 Dizal, a biopharmaceutical company focused on developing targeted oncology therapies, has announced that China’s...